Evidence map›Paper›PMID 14990699›Full record

ArticleJournal of virology2004

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.

Shawn E Kuhmann, Pavel Pugach, Kevin J Kunstman, Joann Taylor, Robyn L Stanfield, Amy Snyder, Julie M Strizki, Janice Riley, Bahige M Baroudy, Ian A Wilson and 3 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 96 papers.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 197 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Shawn E KuhmannDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA.
Pavel Pugach
Kevin J Kunstman
Joann Taylor
Robyn L Stanfield
Amy Snyder
Julie M Strizki
Janice Riley
Bahige M Baroudy
Ian A Wilson
Bette T Korber
Steven M Wolinsky
John P Moore
Cornell University · USNorthwestern University · USLos Alamos National Laboratory · USSanta Fe Institute · USScripps Research Institute · US

Funding

SECOND RECEPTORS FOR PRIMATE IMMUNODEFICIENCY VIRUSESR01AI041420 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 1997 to 2015
$7.3M
X-ray structures of HIV-1 neutralizing sitesR01GM046192 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI WILSON, IAN A · 1991 to 2008
$3.7M
IMMUNOLOGY RESEARCH TRAINING PROGRAMT32AI007621 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI CESARMAN, ETHEL · 1999 to 2014
$3.4M
VIRAL AND T CELL DYNAMICS IN HIV 1 INFECTED CHILDRENR01HD037356 · NICHD · NORTHWESTERN UNIVERSITY · PI WOLINSKY, STEVEN M · 1999 to 2003
$2.0M
NIAID NIH HHS R01 AI041420NIAID NIH HHS T32 AI007621NIAID NIH HHS T32 AI07621NICHD NIH HHS HD37356NICHD NIH HHS R01 HD037356NIGMS NIH HHS GM46192NIGMS NIH HHS R01 GM046192
6 · The paper itself

Abstract

We have described previously the generation of an escape variant of human immunodeficiency virus type 1 (HIV-1), under the selection pressure of AD101, a small molecule inhibitor that binds the CCR5 coreceptor (A. Trkola, S. E. Kuhmann, J. M. Strizki, E. Maxwell, T. Ketas, T. Morgan, P. Pugach, S. X. L. Wojcik, J. Tagat, A. Palani, S. Shapiro, J. W. Clader, S. McCombie, G. R. Reyes, B. M. Baroudy, and J. P. Moore, Proc. Natl. Acad. Sci. USA 99:395-400, 2002). The escape mutant, CC101.19, continued to use CCR5 for entry, but it was at least 20,000-fold more resistant to AD101 than the parental virus, CC1/85. We have now cloned the env genes from the the parental and escape mutant isolates and made chimeric infectious molecular clones that fully recapitulate the phenotypes of the corresponding isolates. Sequence analysis of the evolution of the escape mutants suggested that the most relevant changes were likely to be in the V3 loop of the gp120 glycoprotein. We therefore made a series of mutant viruses and found that full AD101 resistance was conferred by four amino acid changes in V3. Each change individually caused partial resistance when they were introduced into the V3 loop of a CC1/85 clone, but their impact was dependent on the gp120 context in which they were made. We assume that these amino acid changes alter how the HIV-1 Env complex interacts with CCR5. Perhaps unexpectedly, given the complete dependence of the escape mutant on CCR5 for entry, monomeric gp120 proteins expressed from clones of the fully resistant isolate failed to bind to CCR5 on the surface of L1.2-CCR5 cells under conditions where gp120 proteins from the parental virus and a partially AD101-resistant virus bound strongly. Hence, the full impact of the V3 substitutions may only be apparent at the level of the native Env complex.

Indexed as

CCR5 Receptor AntagonistsDrug Resistance, ViralAmino Acid SequenceAnti-HIV AgentsGenotypeHIV-1HIV Envelope Protein gp120HIV Envelope Protein gp160HIV InfectionsHumansMolecular Sequence DataMutagenesis, Site-DirectedPeptide FragmentsPhenotypeReceptors, CCR5Recombinant Fusion ProteinsAnti-HIV AgentsCCR5 Receptor AntagonistsHIV Envelope Protein gp120HIV envelope protein gp120 (305-321)HIV Envelope Protein gp160Peptide FragmentsReceptors, CCR5Recombinant Fusion Proteins

Identifiers

PMID14990699
PMCPMC353740
OpenAlexW2135581465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.